{
  "id": "7047dd7b3081041e",
  "title": "Tukysa May Be  Patient Friendly  Frontline Maintenance Option in HER2+ Breast Cancer",
  "description": "20260112T144500Z",
  "content": "",
  "source": "curetoday.com",
  "source_url": "https://www.curetoday.com/view/tukysa-may-be-patient-friendly-frontline-maintenance-option-in-her2-breast-cancer",
  "published_at": "20260112T144500Z",
  "fetched_at": "2026-01-13T00:20:01.657666+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "ai"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://www.curetoday.com/view/tukysa-may-be-patient-friendly-frontline-maintenance-option-in-her2-breast-cancer",
    "url_mobile": "",
    "title": "Tukysa May Be  Patient Friendly  Frontline Maintenance Option in HER2+ Breast Cancer",
    "seendate": "20260112T144500Z",
    "socialimage": "https://cdn.sanity.io/images/0vv8moc6/curetoday/83a35f00fbfba07f368abc694158eb25ac06f360-1280x720.jpg",
    "domain": "curetoday.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}